Budesonide - a new steroid for intranasal use. A double-blind clinical comparison between budesonide and placebo in patients with seasonal allergic rhinitis.
Twenty-nine patients with seasonal rhinitis completed a double-blind study comparing budesonide nasal spray 200 micrograms b.i.d. with placebo. The patients were randomly assigned into two parallel groups. Symptoms were assessed over a treatment period of 3 weeks. There were statistically significant differences in favour of budesonide on all measurements. Side effects were mild and the incidence was low.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D019819:Budesonide; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011282:Pregnenediones / Q000009:adverse effects / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D013256:Steroids / Q000627:therapeutic use*
D010919:Placebos; D011282:Pregnenediones; D013256:Steroids; D019819:Budesonide